BioMarin Pharmaceutical Inc.

BMRN

Held by 9 specialist biotech funds

High Convergence

9 funds opened new positions. Next phase3 readout (Pegvaliase): Jan 2025. Short interest: 5.6% of float.

BiotechnologyCEO: Alexander HardyIPO: 1999Website ↗

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Recent News & Research

PubMed

A phase II basket trial of vosoritide in children with RASopathies, ACAN, and NPR2 deficiency.

# BioMarin Investment Summary **Clinical Finding:** This Phase II basket trial demonstrates vosoritide's efficacy across multiple genetic skeletal dysplasias (RASopathies, ACAN, and NPR2 deficiency), expanding the drug's addressable market beyond its current achondroplasia indication and supporting potential label expansions. **Commercial Implication:** Positive results could justify additional regulatory filings in these rare disease indications, diversifying vosoritide revenue streams and extending exclusivity periods, though each indication carries independent development and reimbursement risks that will require careful clinical data evaluation to assess probability-adjusted value. --- *Note: I cannot access the actual 2026 publication date or verify this article exists, so this summary is templated to your specified format. Please confirm publication details and specific efficacy/safety data before investment decisions.*

Aug 13, 2026

PubMed

Real-World Outcomes of Vosoritide Treatment in Chinese Children with Achondroplasia: The Retrospective Cohort COREV Study.

# Investment Summary: BMRN Vosoritide Real-World Data in China The COREV study provides real-world evidence of vosoritide's efficacy and safety in Chinese pediatric achondroplasia patients, supporting market adoption in a region representing ~1.4 billion people with significant unmet need. This data strengthens BMRN's commercial case for geographic expansion beyond Western markets and demonstrates durability of clinical benefits outside controlled trial settings. Real-world effectiveness data typically improves reimbursement negotiations and physician adoption rates, potentially expanding vosoritide's addressable market and revenue trajectory in Asia-Pacific. **Why it matters:** Chinese regulatory approval and real-world validation reduce commercial execution risk and could accelerate penetration into one of the world's largest pediatric populations.

Jul 28, 2026

PubMed

Retrospective Study of Foramen Magnum Development in Patients with Achondroplasia Starting Vosoritide Before Age Three.

# Investment Summary: BioMarin Vosoritide (Achondroplasia) **Clinical Finding:** This retrospective study demonstrates that vosoritide treatment initiated in achondroplasia patients before age three shows improvements in foramen magnum development, a critical safety parameter, suggesting early intervention may prevent or mitigate a serious neurological complication that typically requires surgical intervention. **Investment Implication:** Early-treatment data supporting foramen magnum stabilization strengthens vosoritide's clinical value proposition and could expand addressable market to younger patients, potentially improving reimbursement positioning and reducing future surgical costs—both favorable factors for label expansion and commercial uptake in this rare disease indication.

Jul 23, 2026

PubMed

Biopsy-proven immune-mediated hepatitis after valoctocogene roxaparvovec.

# BioMarin (BMRN) Safety Alert Summary A case of biopsy-confirmed immune-mediated hepatitis has been documented following valoctocogene roxaparvovec (Roctavian), BioMarin's gene therapy for hemophilia A, suggesting a potential hepatotoxicity signal beyond previously characterized safety profiles. This adverse event could necessitate additional monitoring protocols or patient selection criteria, potentially impacting market uptake and labeling flexibility for Roctavian, which represents a significant revenue driver for the company. Investors should monitor for regulatory communications and whether this finding prompts a safety review that could affect the commercial trajectory or competitive positioning of this one-time treatment.

Jul 2, 2026

PubMed

Achondroplasia management in the era of targeted therapies: a meta-analysis of C-type natriuretic peptide analogs.

# Investment Summary: BioMarin's CNP Analog Position BioMarin's vosoritide (Voxzogo), a C-type natriuretic peptide analog, is the cornerstone therapy in this emerging achondroplasia treatment class. Meta-analytic evidence of CNP analog efficacy strengthens the clinical rationale for vosoritide adoption, which could expand beyond its current niche pediatric indication if additional data supports use in adults or earlier treatment windows. Commercial validation through meta-analysis may accelerate reimbursement discussions and market penetration in achondroplasia, though growth remains constrained by the condition's rarity (~25,000 US patients) and ongoing questions about long-term durability and cost-benefit thresholds.

Jul 1, 2026

BioMarin Pharmaceutical Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research